THE ROLE OF GUT MICROBIOTA ALTERATIONS IN THE DEVELOPMENT OF HEPATIC ENCEPHALOPATHY IN PATIENTS WITH LIVER CIRRHOSIS
Keywords:
liver cirrhosis, gut microbiota, dysbiosis, gut–liver axis, metabolic disorders, toxic metabolites, opportunistic bacteria, liver function, microecologyAbstract
This article is devoted to the study of structural changes in the gut microbiota of patients with liver cirrhosis and their impact on the course of the disease. During the progression of liver cirrhosis, disruption of the intestinal microecological balance may lead to alterations in metabolic processes and further deterioration of liver function. In this article, qualitative and quantitative changes in the gut microbiota were analyzed. The findings demonstrated that dysbiosis, characterized by a reduction in beneficial bacteria and an increase in certain opportunistic microorganisms, is widespread among patients with liver cirrhosis. Such alterations in the gut microbiota may contribute to dysfunction of the gut–liver axis and create conditions for the accumulation of toxic metabolites in the body. Furthermore, changes in microbiota composition were found to be associated with the clinical course and severity of the disease. The conclusions obtained indicate that the assessment of gut microbiota is of significant importance in determining the developmental characteristics of liver cirrhosis. The study findings provide a scientific basis for improving preventive and therapeutic approaches aimed at restoring intestinal microecology.
References
Ouyang Li 1 2, Han Xu 1 3, Dayoung Kim 1 3, Fan Yang 1 3, Zhijun Bao 1 2 3
Shanghai Key Laboratory of Clinical Geriatric Medicine, Shanghai, China
Department of Gastroenterology, Huadong Hospital Affiliated to Fudan University, Shanghai, China
Department of Gerontology, Huadong Hospital Affiliated to Fudan University, Shanghai, China
Received 9 August 2023, Revised 26 October 2023, Accepted 3 November 2023, Available online 19 November 2023, Version of Record 10 January 2024.
Bajaj JS, et al. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Frontiers in Cellular and Infection Microbiology. 2022.
Study on causal relationship between gut microbiota and hepatic encephalopathy. BMC Medical Genomics. 2024.
Rifaximin’s effects on hepatic encephalopathy and gut microbiota composition. Clinical and Translational Gastroenterology. 2016; Rifaximin, Microbiota Biology, and Hepatic Encephalopathy.
Zhu R, Liu L, Zhang G, et al. The pathogenesis of gut microbiota in hepatic encephalopathy by the gut–liver–brain axis. Bioscience Reports. 2023.
LE Y, et al. Gut microbiota regulation and diet therapy for hepatic encephalopathy. Journal of Clinica
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. Francesca Romanda Ponziani, Viviana Gerardi, Silvia Pecere, Francesca DʼAversa, Loris Lopetuso, Maria Assunta Zocco, Maurizia Pompili, Antonio Gasbarrini, 2015.
Roles of Human Gut Microbiota in Liver Cirrhosis Risk: A Two-Sample Mendelian Randomization Study.Ouyang Li, Han Xu, Dayoung Kim, Fan Yang, Zhijun Bao, 2024.
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in IQRO — Scientific Methodological Journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Authors retain copyright and grant the journal the right of first publication.
Users may read, download, copy, distribute, print, search, or link to the full texts of articles, provided that the original authors and the journal are properly cited.
Published materials may be used, distributed, and reproduced in any medium, provided that the original work is properly cited.



Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo